Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.

Following a data breach and bankruptcy, genetic testing service 23andMe will soon be in different hands. On Monday, biotechnology company Regeneron announced that it won the top bid in a ...

Regeneron said Monday it will “prioritize the privacy, security and ethical use” of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt ...

A slump in Japanese bonds worsened Tuesday after the weakest demand at a government debt auction in more than a decade highlighted worries over the central bank’s retreat from the market.

TOKYO -- The market dynamics for Japan's ultralong-term bonds have deteriorated sharply as the number of buyers continues to shrink. In fiscal 2024, net purchases by life and non-life insurers ...

TOKYO, May 20 (Reuters) - Some market players urged the Bank of Japan to increase buying of super-long bonds, or terminate tapering for that maturity, in the wake of sharp rises in their yields ...

TOKYO -- The Japanese government plans to roughly double the capacity of underground bomb shelters nationwide to 10 million people, in an effort to better safeguard the public from missile ...

Weak economic sentiment could be a buy signal, Bank of America says. The market historically soars when weak sentiment fails to trigger a recession. BofA expects this to be the case this year ...

TOKYO, May 20 (Reuters) - Honda Motor (7267.T), opens new tab said on Tuesday that it was scaling back its investment in electric vehicles given slowing demand and would be focusing on hybrids ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s ...